{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.17","upperLimit":"11.07","value":"6.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in"}],"paramType":"MEDIAN","populationDescription":"The SLI Efficacy Set consisted of all CSLI participants in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing). Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)","title":"(Safety Lead-in) Duration of Response (DOR) by Investigator","type":"SECONDARY","unitOfMeasure":"Months"}